Artificial Vascular Grafts MarketSize, Share & Industry Analysis, 2026-2034By ProductBy Raw MaterialBy ApplicationBy End UserBy Distribution Channel

Artificial vascular grafts are prosthetic or biologically derived tubular conduits implanted to replace or bypass diseased, damaged or occluded blood vessels. They are manufactured from synthetic polymers such as expanded polytetrafluoroethylene and polyester, or from processed biological tissue, and are supplied in a range of diameters and lengths to match the vessel being repaired. Buyers include vascular and cardiac surgeons, interventional radiologists and hospital procurement teams who select a graft based on the procedure being performed, whether hemodialysis access creation, aneurysm repair, peripheral bypass or coronary bypass surgery.

The global artificial vascular grafts market stood at USD 2.05 billion in 2025. A forecast-period rate of 7.38% takes it to USD 3.89 billion by 2034, and the study reports every year in between, passing USD 1.42 billion in 2020, USD 1.91 billion in 2024, USD 2.2 billion in 2026 and USD 2.94 billion in 2030.

Composition changes more than the total does. Endovascular Stent Graft, at 8.65%, outgrows Coronary Artery By-pass Graft at 5.2%, and its share moves from 37.56% to 41.9%. Endovascular Stent Graft stays the largest line throughout, at USD 0.77 billion in 2025 and USD 1.63 billion in 2034. Endovascular Stent Graft take share over the period; Hemodialysis Access Graft, Peripheral Vascular Graft and Coronary Artery By-pass Graft give it up while still growing in absolute terms.

Cut by raw material, the largest line is Synthetic Raw Material: 78.05% of 2025 revenue, worth USD 1.6 billion, and 74.04% at USD 2.88 billion by 2034. Biological Raw Material grows faster at 9.4% against 6.75%, moving from 21.95% of revenue to 25.96% by 2034. Both this axis and the product one divide the same revenue, which is why they are alternative views, not components.

The regional order runs from North America at 38.54% of 2025 revenue down to Middle East and Africa at 4.88%. North America is worth USD 0.79 billion in 2025 and USD 1.32 billion in 2034; Europe, second at 26.83%, moves from USD 0.55 billion to USD 0.97 billion. Because Asia Pacific and Latin America take share, the revenue added by 2034 concentrates instead of spreading across all five regions.

The 2025 total is arrived at by triangulating published aggregates against category proxies, not by an independent count. Segment, regional and country splits are estimated on the same basis, which bounds the precision of the figures above. Coverage runs to five regions, four product lines and five segmentation axes across a fifteen-year window.

• Revenue grows from USD 2.05 billion in 2025 to USD 3.89 billion in 2034, a compound annual rate of 7.38%, having reached USD 1.91 billion in 2024 from USD 1.42 billion in 2020.
• Endovascular Stent Graft is the largest product line at USD 0.77 billion in 2025, a 37.56% share, reaching USD 1.63 billion and 41.9% of revenue by 2034.
• The bull case puts 2034 revenue at USD 4.51 billion and the bear case at USD 3.37 billion, either side of the USD 3.89 billion base case, each with its own stated assumption in the full report.
• 38.54% of 2025 revenue is generated in North America, worth USD 0.79 billion and rising to USD 1.32 billion by 2034; Middle East and Africa is smallest at 4.88%.
• The United States accounts for 82.28% of North America in the base year, worth USD 0.65 billion in 2025 and reaching USD 1.06 billion by 2034, the worked country example carried through that region's chapters.
• Fifteen years are reported, 2020 to 2034 with 2025 as the base: revenue, share and growth rate per line, per axis and per region, not as a single blended series.

The global artificial vascular grafts market is shaped over 2026-2034 by three measurable movements: a change in the product mix, a shift in where revenue sits geographically, and the 7.38% rate carrying the total.

The direction of the market is not in question in any of the three. Each line and each region grows in revenue terms; what separates them is which takes the larger part of the growth.

Composition shifts on the product axis. Between 2026 and 2034, 8.65% growth in Endovascular Stent Graft against 5.2% in Coronary Artery By-pass Graft pulls the product mix apart. Shares follow: 37.56% to 41.9% for Endovascular Stent Graft, 12.2% to 10.03% for Coronary Artery By-pass Graft. Neither contracts: USD 0.77 billion becomes USD 1.63 billion, USD 0.25 billion becomes USD 0.39 billion. What the spread decides is which of them a supplier's revenue is exposed to.

Asia Pacific and Latin America gain regional share. Asia Pacific moves from 23.9% of revenue in 2025 to 30.08% in 2034, worth USD 0.49 billion rising to USD 1.17 billion; Latin America moves from 5.85% of revenue in 2025 to 6.43% in 2034, worth USD 0.12 billion rising to USD 0.25 billion. Against that, North America at 38.54% moving to 33.93%, Europe at 26.83% moving to 24.94%, Middle East and Africa at 4.88% moving to 4.63%, a fall in share, not in revenue. That makes the regional split worth reading directly instead of scaling from the global rate: the same market rate produces different outcomes depending on where a supplier's revenue sits.

A continuation, not an inflection. Year by year the total runs USD 1.42 billion in 2020, USD 1.91 billion in 2024, USD 2.05 billion in 2025, USD 2.2 billion in 2026, USD 2.94 billion in 2030 and USD 3.89 billion in 2034. No year breaks the trajectory, and the 7.38% forecast rate compares with 7.62% recorded over 2020-2025, a continuation, not an inflection. For a participant that makes planning a question of capturing a share of steady expansion instead of timing a discontinuity, and it is why the product and regional mixes matter more to a forecast than the headline rate does.

Growth is concentrated in Endovascular Stent Graft

Three sources account for the growth to 2034: 7.38% compounding across the base, share moving toward the faster product lines, and above-market expansion in the leading regions.

Downside case: USD 3.37 billion by 2034, against USD 3.89 billion in the base case

Upside case: USD 4.51 billion by 2034

Revenue is concentrated in Endovascular Stent Graft

USD 0.79 billion of 2025 revenue is generated in North America, 38.54% of the global artificial vascular grafts market rising to USD 1.32 billion in 2034. It is a dominant region on this axis, first by revenue throughout the period.

By 2034 the share stands at 33.93%, and the region keeps growing in absolute terms while others expand faster, a change in relative weight, not a decline in demand.

Within the region the product split tracks the global one; 37.56% of 2025 revenue in Endovascular Stent Graft, fastest growth of 8.65% in Endovascular Stent Graft. Revenue for North America is broken out by every segmentation axis and by country in the full report.

USD 0.65 billion of North America's 2025 revenue is generated in the United States, the region's largest market, reaching USD 1.06 billion by 2034. Because it is 82.28% of the region in the base year, North America's totals move with this one country instead of a spread of them. Against regional totals of USD 0.79 billion in 2025 and USD 1.32 billion in 2034, it is the country the full report breaks out in detail.

the United States buys along the same lines as the market globally; Endovascular Stent Graft first at 37.56% of 2025 revenue and 41.9% in 2034, Endovascular Stent Graft fastest at 8.65% on a share moving from 37.56% to 41.9%. With 82.28% of North America concentrated here, a change in this country's mix is visible in the regional figures instead of being diluted by its neighbours. The United States carries its own product breakdown in the full report.

Artificial vascular grafts fall under the Food and Drug Administration's medical device framework and are treated as a Class II or Class III product depending on the specific design and intended use, which determines whether clearance proceeds through the premarket notification pathway or the more demanding premarket approval route requiring clinical evidence of safety and effectiveness. Manufacturers must operate under the Quality System Regulation covering design controls, production, and post-market surveillance, and devices must carry labeling that identifies materials, sterility status, and intended indications. Conformity with recognized consensus standards for vascular prosthesis performance is expected to support a submission. Adverse event reporting and facility registration obligations continue after a device reaches the market.

Competition in the United States runs between the suppliers this study tracks: Artegraft, TERUMO CORPORATION, Heart Medical, BD, Cook Group, Medtronic, Cardinal Health, Suokang, Maquet and LifeNet Health. Volume and growth sit in the same line, Endovascular Stent Graft, at 37.56% of 2025 revenue and 8.65% growth. Country-level shares and positioning per company sit in the full report.

6.83% of global revenue is generated in Canada; USD 0.14 billion in 2025, reaching USD 0.26 billion in 2034, and 17.72% of North America.

USD 0.55 billion of 2025 revenue is generated in Europe, 26.83% of the global artificial vascular grafts market and reaches USD 0.97 billion by 2034. It is a leading region on this axis, second by revenue throughout the period.

24.94% of global revenue sits here in 2034, below the 2025 level, though revenue still rises throughout; the shift is in the region's weight against faster-growing ones, which is not the same as weakening demand.

The product mix reported at global level applies here, with Endovascular Stent Graft the largest line at 37.56% of 2025 revenue and Endovascular Stent Graft the fastest-growing at 8.65%. Revenue for Europe is broken out by every segmentation axis and by country in the full report.

USD 0.17 billion of Europe's 2025 revenue is generated in Germany, the region's largest market, reaching USD 0.29 billion by 2034. At 30.91% of the region in 2025 it leads, but a majority of Europe's revenue is generated in other markets. Against regional totals of USD 0.55 billion in 2025 and USD 0.97 billion in 2034, it is the country the full report breaks out in detail.

The product pattern in Germany is the global one: 37.56% of 2025 revenue in Endovascular Stent Graft, 41.9% by 2034, against 8.65% growth in Endovascular Stent Graft taking it from 37.56% to 41.9%. Its 30.91% weight in Europe means those movements carry straight into the regional totals. Revenue by product for Germany is reported separately in the full report.

As a European Union member state, Germany applies the Medical Device Regulation to artificial vascular grafts, which are classified as implantable devices subject to the highest conformity assessment tier given their invasive, long-term contact with the body. A manufacturer must engage a notified body to assess technical documentation, clinical evaluation data, and quality management systems before affixing the CE mark, and an authorized representative or responsible person must be designated for market placement. Labelling must include an implant card provided to the patient, along with instructions for use meeting the regulation's language and content requirements. Compliance with harmonized standards for vascular implants supports the clinical evaluation, and the national competent authority oversees vigilance reporting and market surveillance once the product is placed.

The suppliers tracked in this study (Artegraft, TERUMO CORPORATION, Heart Medical, BD, Cook Group, Medtronic, Cardinal Health, Suokang, Maquet and LifeNet Health) compete in Germany across the product lines above. Endovascular Stent Graft is where the volume is, at 37.56% of 2025 revenue, and it is growing fastest as well at 8.65%. A supplier weighted toward Europe is competing over a base of USD 0.55 billion in 2025 reaching USD 0.97 billion by 2034, 26.83% of global revenue at the start of that period.

The United Kingdom is sized at USD 0.13 billion in 2025, rising to USD 0.22 billion by 2034; 6.34% of global revenue and 23.64% of Europe. It is reported separately from Germany across every segmentation axis in the full report.

Within Europe, France accounts for 20% of regional revenue and 5.37% of the global total, worth USD 0.11 billion in 2025 and USD 0.18 billion by 2034.

USD 0.49 billion of 2025 revenue is generated in Asia Pacific, 23.9% of the global artificial vascular grafts market on the way to USD 1.17 billion by 2034. It is a leading region on this axis, third by revenue throughout the period.

30.08% of global revenue sits here by 2034, up from the 2025 level, because it outgrows the market's 7.38%; the revenue added here is disproportionate to where the region started.

Segment composition follows the global pattern: Endovascular Stent Graft largest at 37.56% of 2025 revenue, Endovascular Stent Graft fastest at 8.65%. Revenue for Asia Pacific is broken out by every segmentation axis and by country in the full report.

The largest single market in Asia Pacific is China, at USD 0.21 billion in 2025 and USD 0.5 billion in 2034. Its 42.86% of base-year regional revenue leads the region, though enough sits elsewhere that Asia Pacific is not a proxy for it. Regional revenue of USD 0.49 billion in 2025 and USD 1.17 billion in 2034 sits around it, and it is the country used wherever the full report cuts a figure by geography.

China buys along the same lines as the market globally; Endovascular Stent Graft first at 37.56% of 2025 revenue and 41.9% in 2034, Endovascular Stent Graft fastest at 8.65% on a share moving from 37.56% to 41.9%. Since 42.86% of Asia Pacific's revenue is generated here, the regional numbers inherit this market's mix instead of smoothing it out. The full report reports China by product separately.

The National Medical Products Administration governs artificial vascular grafts in China, classifying them as higher-risk implantable devices that require premarket registration rather than simple filing. An applicant must submit clinical evaluation data, often including local clinical trials conducted within China, together with technical documentation demonstrating biocompatibility, mechanical performance, and manufacturing quality under the national good manufacturing practice requirements for medical devices. Labelling and instructions for use must appear in Chinese and disclose material composition and intended indications. A domestic agent is required for overseas manufacturers seeking registration, and post-market obligations include adverse event monitoring and periodic reassessment tied to registration renewal cycles set by the regulator.

In China the field is Artegraft, TERUMO CORPORATION, Heart Medical, BD, Cook Group, Medtronic, Cardinal Health, Suokang, Maquet and LifeNet Health. Endovascular Stent Graft is both the largest line, at 37.56% of 2025 revenue, and the fastest-growing at 8.65%. The commercial size of that position is USD 0.49 billion in 2025, moving to USD 1.17 billion by 2034 across the forecast period.

Japan is sized at USD 0.12 billion in 2025, rising to USD 0.26 billion by 2034; 5.85% of global revenue and 24.49% of Asia Pacific. It is reported separately from China across every segmentation axis in the full report.

3.41% of global revenue is generated in India; USD 0.07 billion in 2025, reaching USD 0.2 billion in 2034, and 14.29% of Asia Pacific.

In Latin America, 5.85% of global revenue puts 2025 at USD 0.12 billion with USD 0.25 billion projected for 2034. By revenue it sits fourth across the study, and the ranking does not change between 2025 and 2034.

By 2034 the share has moved up to 6.43%, because it outgrows the market's 7.38%; the revenue added here is disproportionate to where the region started.

Segment composition follows the global pattern: Endovascular Stent Graft largest at 37.56% of 2025 revenue, Endovascular Stent Graft fastest at 8.65%. The full report breaks Latin America out along every axis and by country.

The largest single market in Latin America is Brazil, at USD 0.07 billion in 2025 and USD 0.14 billion in 2034. Its 58.33% of base-year regional revenue leads the region, though enough sits elsewhere that Latin America is not a proxy for it. Against regional totals of USD 0.12 billion in 2025 and USD 0.25 billion in 2034, it is the country the full report breaks out in detail.

Composition here matches the global split: the largest line is Endovascular Stent Graft at 37.56% of 2025 revenue, easing to 41.9% by 2034, and the fastest is Endovascular Stent Graft at 8.65%, from 37.56% to 41.9%. Since 58.33% of Latin America's revenue is generated here, the regional numbers inherit this market's mix instead of smoothing it out. Brazil carries its own product breakdown in the full report.

Brazil's health surveillance agency, ANVISA, regulates artificial vascular grafts as implantable medical devices requiring registration before commercial distribution. The pathway calls for technical dossiers covering design, materials, sterilization validation, and clinical evidence, with risk classification determining the depth of review; implantable vascular products are treated among the higher risk categories given their permanent contact with the cardiovascular system. Good manufacturing practice certification of the production site, whether domestic or foreign, is a prerequisite for registration, and a local registration holder must be designated to interface with the agency. Portuguese-language labelling and instructions for use are mandatory, and the manufacturer remains subject to ongoing vigilance and technovigilance reporting duties after launch.

Competition in Brazil runs between the suppliers this study tracks: Artegraft, TERUMO CORPORATION, Heart Medical, BD, Cook Group, Medtronic, Cardinal Health, Suokang, Maquet and LifeNet Health. One line leads on both counts here: Endovascular Stent Graft holds 37.56% of 2025 revenue and compounds fastest at 8.65%. The commercial size of that position is USD 0.12 billion in 2025, moving to USD 0.25 billion by 2034 across the forecast period.

Within Latin America, Mexico accounts for 33.33% of regional revenue and 1.95% of the global total, worth USD 0.04 billion in 2025 and USD 0.08 billion by 2034.

In Middle East and Africa, 4.88% of global revenue puts 2025 at USD 0.1 billion with USD 0.18 billion projected for 2034. It is a marginal region on this axis, fifth by revenue throughout the period.

4.63% of global revenue sits here in 2034, below the 2025 level, though revenue still rises throughout; the shift is in the region's weight against faster-growing ones, which is not the same as weakening demand.

Endovascular Stent Graft leads here as it does globally, at 37.56% of 2025 revenue, and Endovascular Stent Graft again grows fastest at 8.65%. Middle East and Africa is reported axis by axis and country by country in the full study.

USD 0.04 billion of Middle East and Africa's 2025 revenue is generated in Saudi Arabia, the region's largest market, reaching USD 0.08 billion by 2034. It accounts for 40% of regional revenue in the base year, the largest single share without dominating the region outright. The region itself runs USD 0.1 billion to USD 0.18 billion over the same period, and this is the market carrying the country-level detail in the full report.

Demand in Saudi Arabia follows the product mix reported at global level: Endovascular Stent Graft is the largest line at 37.56% of 2025 revenue, moving to 41.9% by 2034, while Endovascular Stent Graft grows fastest at 8.65% and takes its share from 37.56% to 41.9%. Its 40% weight in Middle East and Africa means those movements carry straight into the regional totals. Revenue by product for Saudi Arabia is reported separately in the full report.

The Saudi Food and Drug Authority regulates artificial vascular grafts through its medical devices framework, which draws heavily on international risk-classification principles and requires listing of the device along with evidence of conformity to recognized international standards before market authorization is granted. A local authorized representative established in the Kingdom is generally required to submit and maintain the registration on the manufacturer's behalf, and the applicant must furnish evidence of quality management system certification and, where applicable, prior approval or clearance from a recognized reference regulatory authority. Labelling must appear in Arabic alongside the original language, disclosing composition, sterility, and intended use. Post-market surveillance and incident reporting obligations apply once the device is in distribution.

The suppliers tracked in this study (Artegraft, TERUMO CORPORATION, Heart Medical, BD, Cook Group, Medtronic, Cardinal Health, Suokang, Maquet and LifeNet Health) compete in Saudi Arabia across the product lines above. One line leads on both counts here: Endovascular Stent Graft holds 37.56% of 2025 revenue and compounds fastest at 8.65%. A supplier weighted toward Middle East and Africa is competing over a base of USD 0.1 billion in 2025, reaching USD 0.18 billion by 2034 on the trajectory this study models.

South Africa is sized at USD 0.03 billion in 2025, rising to USD 0.04 billion by 2034; 1.46% of global revenue and 30% of Middle East and Africa. It is reported separately from Saudi Arabia across every segmentation axis in the full report.

Request this sample to see the full data tables and segment-level detail behind this analysis.

This report assesses the market across every segment, with revenue and a growth rate for each line in each year of the study period. It covers the drivers, trends, opportunities, restraints and challenges shaping growth, the competitive landscape and the companies profiled, and the research methodology behind every estimate. Segmentation is reported by Product, Raw Material, Application, End User, Distribution Channel, and regional analysis covers North America, Europe, Asia Pacific, Latin America, Middle East and Africa, each broken out by country.